Barclays Maintains Teva Pharmaceutical Industries(TEVA.US) With Buy Rating, Maintains Target Price $22
Argus Research Maintains Teva Pharmaceutical Industries(TEVA.US) With Buy Rating
Evercore Maintains Teva Pharmaceutical Industries(TEVA.US) With Buy Rating
Barclays Maintains Teva Pharmaceutical Industries(TEVA.US) With Buy Rating, Raises Target Price to $22
Teva Pharmaceutical Indus Analyst Ratings
BofA Securities Maintains Teva Pharmaceutical Industries(TEVA.US) With Buy Rating, Maintains Target Price $21
Barclays Sticks to Its Buy Rating for Teva Pharmaceutical (TEVA)
Piper Sandler Maintains Teva Pharmaceutical Industries(TEVA.US) With Buy Rating, Maintains Target Price $20
Teva Pharmaceutical Indus Analyst Ratings
Argus Upgrades Teva to Buy, Cites Recent Drug Approvals
Teva Pharmaceutical Indus Analyst Ratings
Teva Pharmaceutical Indus Analyst Ratings
Teva Pharmaceutical Indus Analyst Ratings
Teva Pharmaceutical Indus Analyst Ratings
Teva Pharmaceutical Indus Analyst Ratings
Teva Upgraded at J.P. Morgan on Upcoming Catalysts
Teva Pharmaceutical Indus Analyst Ratings
Teva Pharmaceutical Indus Analyst Ratings
Teva Pharmaceutical Indus Analyst Ratings
UBS Remains a Buy on Teva Pharmaceutical (TEVA)